Key PointsViking Therapeutics has a dual GLP-1/GIP agonist in Phase 2 clinical trials for treating obesity and liver fat reduction for injectable and oral administration.Rhythm Pharmaceuticals has an FDA-approved treatment for the treatment of MC4R-pathway-related obesity disorders, including Bardet-Biedl Syndrome (BBS) and hyperphagia, an extreme, uncontrollable and compulsive compulsion to eat.Rhythm is a Phase 3 clinical trial for hypothalamic disorder (HO), a type of obesity caused by a damaged hypothal ...

The Altimmune (NASDAQ: ALT) stock price has been in a strong uptrend in the past few months. It bottomed at $2.07 in October, and the shares have surged by over 475% to its highest level since February. This rally has brought its total market cap to more than $629 million.Why is ALT shares soaring?Copy link to sectionAltimmune share price has been in a strong uptrend in the past few months as demand for weight loss drugs continued rising. Its drug, known as Pemvidutide, which it acquired in 2019, has shown ...

Biotech is still one of the most exciting investments on the market, creating substantial opportunities for some of the best biotech stocks.Look at obesity drug stocks, like Eli Lilly (NYSE:LLY) for example. The stock exploded from about $460 to a high of $626 just over excitement with its obesity treatment. After all, with obesity bursting at the seams, many are excited about the idea of a drug that can help them shed extra pounds. Or, look at gene-editing stocks, like CRISPR Therapeutics (NASDAQ:CRSP), wh ...

Altimmune, Inc. (NASDAQ:ALT) Q3 2023 Earnings Conference Call November 7, 2023 8:30 AM ET Company Participants Rich Eisenstadt - Chief Financial Officer Vipin Garg - Chief Executive Officer Scott Harris - Chief Medical Officer Scot Roberts - Chief Scientific Officer Conference Call Participants Yasmeen Rahimi - Piper Sandler Roger Song - Jefferies William Wood - B. Riley Jonathan Wolleben - JMP Securities Louis Susser - H. C. Wainwright Operator Good day, ladies and gentlemen, and welcome to the Altimmune, ...

ALTIMMUNE, INC. CORPORATE PRESENTATION November 2023 ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-32587 ALTIMMUNE, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 20-2726770 (State or ...

Financial Data and Key Metrics Changes - Altimmune ended Q2 2023 with approximately $160 million in cash, cash equivalents, and short-term investments, down from $184.9 million at the end of 2022 [20] - Research and development expenses were $13.3 million in Q2 2023, compared to $16 million in the same period in 2022 [20] - Net loss for Q2 2023 was $16.1 million or $0.32 net loss per share, an improvement from a net loss of $20.1 million or $0.42 net loss per share in Q2 2022 [21] Business Line Data and Key Metrics Changes - Pemvidutide, the lead product candidate, showed a greater than 75% relative reduction in liver fat at 24 weeks in the Phase 1b trials, with over 50% of subjects achieving normalization of liver fat in the 1.8 mg dose group [7] - In the Phase 2 MOMENTUM trial, interim results indicated weight loss of 10.7% at the 2.4 mg dose and 9.4% at the 1.8 mg dose after 24 weeks, compared to a 1% weight loss in the placebo group [9][16] Market Data and Key Metrics Changes - The obesity market is expected to segment, with increasing demand for novel therapies, as indicated by recent acquisitions in the sector [30][31] - The prevalence of comorbidities such as dyslipidemia and high liver fat content is significant among the obesity population, with 60% to 75% of patients affected [9] Company Strategy and Development Direction - The company is focused on advancing pemvidutide for obesity and NASH, with plans to initiate Phase 3 development in obesity in the second half of next year [38] - Altimmune aims to secure a partner for the development of pemvidutide, targeting both NASH and obesity indications [44] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving significant rates of NASH resolution and fibrosis improvement from the upcoming IMPACT trial, with data readout anticipated in Q1 2025 [7][14] - The company is optimistic about the competitive positioning of pemvidutide in the NASH marketplace, emphasizing the importance of weight loss and liver fat reduction [8][9] Other Important Information - The Phase 2 clinical trial of HepTcell in chronic hepatitis B is expected to report results in Q1 2024, with a focus on antiviral effects [10][18] - The company has completed enrollment in the HepTcell trial, which aims for a 1-log reduction in hepatitis B surface antigen [18] Q&A Session Summary Question: Expectations for weight loss at 48 weeks - Management still targets mid to upper teens for weight loss at 48 weeks, believing that the combination of GLP-1 and glucagon will yield better results than GLP-1 monotherapy [25][26] Question: Update on M&A interest - There is growing interest in M&A, with companies looking for novel obesity mechanisms, and management is encouraged by ongoing discussions with potential partners [30][31] Question: Readiness for Phase 3 obesity trial - The company is preparing for Phase 3 and plans to have a partner lined up before starting the trial [38][39] Question: Comorbidities in trial design - Management believes that the prevalence of comorbidities in the obesity population will facilitate patient recruitment for the trials [39] Question: Ideal partner for pemvidutide development - The ideal partner would be interested in both NASH and obesity indications, as both are metabolic diseases [44] Question: Combinability with existing GLP-1 therapies - Pemvidutide is believed to be safe for use alongside existing GLP-1 therapies, with potential for additional benefits [47][48] Question: NASH resolution and fibrosis improvement at 24 weeks - Management is confident that 24 weeks is sufficient to see benefits in NASH resolution and fibrosis improvement, supported by preclinical data [62][64]

Table of Contents Title of each class Trading Symbol(s) Name of each exchange on which registered Common stock, par value $0.0001 per share ALT The NASDAQ Global Market UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition pe ...

Altimmune, Inc. (NASDAQ:ALT) Q1 2023 Earnings Conference Call May 11, 2023 8:30 AM ET Company Participants Rich Eisenstadt - Chief Financial Officer Vipin Garg - Chief Executive Officer Scott Harris - Chief Medical Officer Scot Roberts - Chief Scientific Officer Conference Call Participants Seamus Fernandez - Guggenheim Securities Yasmeen Rahimi - Piper Sandler Corinne Jenkins - Goldman Sachs Roger Song - Jefferies Liisa Bayko - Evercore ISI Mayank Mamtani - B. Riley Jonathan Wolleben - JMP Securities Patri ...

Table of Contents Title of each class Trading Symbol(s) Name of each exchange on which registered Common stock, par value $0.0001 per share ALT The NASDAQ Global Market UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition p ...